Afeyan Noubar's Form 4 filing
Evelo Biosciences, Inc. (EVLO) · filed Jul 13, 2023
- Accession no.
- 0000950170-23-032871
- Filed
- Jul 13, 2023, 5:15 PM ET
- Trade date
- Jul 11, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $12.5M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Afeyan NoubarCIK 0001222012 | 10% Owner |
| Flagship Pioneering, LLCCIK 0001400240 | 10% Owner |
| Flagship Ventures Fund IV, L.P.CIK 0001503559 | 10% Owner |
| Flagship Ventures Fund IV General Partner LLCCIK 0001508051 | 10% Owner |
| Nutritional Health LTP Fund General Partner LLCCIK 0001780951 | 10% Owner |
| Nutritional Health LTP Fund, L.P.CIK 0001780956 | 10% Owner |
| Flagship Pioneering Fund VII, L.P.CIK 0001805916 | 10% Owner |
| Flagship Pioneering Fund VII General Partner LLCCIK 0001805917 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 11, 2023 | Common Stock | PPurchaseAcquired | +1,082,251 | $2.31 | +$2,499,999.81 | 1,461,795 | Indirect | |
| Jul 11, 2023 | Common Stock | PPurchaseAcquired | +1,082,251 | $2.31 | +$2,499,999.81 | 1,493,241 | Indirect | |
| Jul 11, 2023 | Common Stock | PPurchaseAcquired | +3,246,753 | $2.31 | +$7,499,999.43 | 3,931,685 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.